Literature DB >> 22940489

Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome.

Matthew B Yurgelun1, Rowena Mercado, Margery Rosenblatt, Monica Dandapani, Wendy Kohlmann, Peggy Conrad, Amie Blanco, Kristen M Shannon, Daniel C Chung, Jonathan Terdiman, Stephen B Gruber, Judy E Garber, Sapna Syngal, Elena M Stoffel.   

Abstract

OBJECTIVE: Due to the increased lifetime risk of endometrial cancer (EC), guidelines recommend that women with Lynch syndrome (LS) age ≥ 35 undergo annual EC surveillance or prophylactic hysterectomy (PH). The aim of this study was to examine the uptake of these risk-reducing strategies.
METHODS: The study population included women meeting clinical criteria for genetic evaluation for LS. Data on cancer risk-reducing behaviors were collected from subjects enrolled in two distinct studies: (1) a multicenter cross-sectional study involving completion of a one-time questionnaire, or (2) a single-center longitudinal study in which subjects completed questionnaires before and after undergoing genetic testing. The main outcome was uptake of EC risk-reducing practices.
RESULTS: In the cross-sectional cohort, 58/77 (75%) women at risk for LS-associated EC reported engaging in EC risk-reduction. Personal history of genetic testing was associated with uptake of EC surveillance or PH (OR 17.1; 95% CI 4.1-70.9). Prior to genetic testing for LS, 26/40 (65%) women in the longitudinal cohort reported engaging in EC risk-reduction. At one-year follow-up, 16/16 (100%) mismatch repair (MMR) gene mutation carriers were adherent to guidelines for EC risk-reduction, 9 (56%) of whom had undergone PH. By three-year follow-up, 11/16 (69%) MMR mutation carriers had undergone PH. Among women with negative or uninformative genetic test results, none underwent PH after testing.
CONCLUSIONS: Genetic testing for LS is strongly associated with uptake of EC risk-reducing practices. Women found to have LS in this study underwent prophylactic gynecologic surgery at rates comparable to those published for BRCA1/2 mutation carriers.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22940489      PMCID: PMC3496001          DOI: 10.1016/j.ygyno.2012.08.031

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  46 in total

1.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC).

Authors:  H F Vasen; J P Mecklin; P M Khan; H T Lynch
Journal:  Dis Colon Rectum       Date:  1991-05       Impact factor: 4.585

2.  Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer.

Authors:  C E Bronner; S M Baker; P T Morrison; G Warren; L G Smith; M K Lescoe; M Kane; C Earabino; J Lipford; A Lindblom
Journal:  Nature       Date:  1994-03-17       Impact factor: 49.962

3.  The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma.

Authors:  Isis Dove-Edwin; Dominique Boks; Sheila Goff; Gemma G Kenter; Robert Carpenter; Hans F A Vasen; Huw J W Thomas
Journal:  Cancer       Date:  2002-03-15       Impact factor: 6.860

4.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

5.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

Authors:  Timothy R Rebbeck; Henry T Lynch; Susan L Neuhausen; Steven A Narod; Laura Van't Veer; Judy E Garber; Gareth Evans; Claudine Isaacs; Mary B Daly; Ellen Matloff; Olufunmilayo I Olopade; Barbara L Weber
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

6.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Authors:  Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

7.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.

Authors:  R Fishel; M K Lescoe; M R Rao; N G Copeland; N A Jenkins; J Garber; M Kane; R Kolodner
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

8.  Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome.

Authors:  M Aarnio; J P Mecklin; L A Aaltonen; M Nyström-Lahti; H J Järvinen
Journal:  Int J Cancer       Date:  1995-12-20       Impact factor: 7.396

9.  Mutations of two PMS homologues in hereditary nonpolyposis colon cancer.

Authors:  N C Nicolaides; N Papadopoulos; B Liu; Y F Wei; K C Carter; S M Ruben; C A Rosen; W A Haseltine; R D Fleischmann; C M Fraser
Journal:  Nature       Date:  1994-09-01       Impact factor: 49.962

10.  Gynecologic screening in hereditary nonpolyposis colorectal cancer.

Authors:  Fleur E M Rijcken; Marian J E Mourits; Jan H Kleibeuker; Harry Hollema; Ate G J van der Zee
Journal:  Gynecol Oncol       Date:  2003-10       Impact factor: 5.482

View more
  15 in total

1.  One case of endometrial cancer occurrence: Over 10 years after colon cancer in Lynch family.

Authors:  Jee Yeon Lee; Hyun Joo Kim; Eun Hee Lee; Hyoun Wook Lee; Jong-Won Kim; Min Kyu Kim
Journal:  Obstet Gynecol Sci       Date:  2013-11-15

2.  Quality of life following prophylactic gynecological surgery: experiences of female Lynch mutation carriers.

Authors:  Holly Etchegary; Elizabeth Dicks; Laura Tamutis; Lesa Dawson
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

3.  Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer.

Authors:  Masataka Adachi; Kouji Banno; Megumi Yanokura; Miho Iida; Kanako Nakamura; Yuya Nogami; Kiyoko Umene; Kenta Masuda; Iori Kisu; Arisa Ueki; Akira Hirasawa; Eiichiro Tominaga; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-11-20

Review 4.  Systemic Barriers to Risk-Reducing Interventions for Hereditary Cancer Syndromes: Implications for Health Care Inequities.

Authors:  Kathleen F Mittendorf; Sarah Knerr; Tia L Kauffman; Nangel M Lindberg; Katherine P Anderson; Heather Spencer Feigelson; Marian J Gilmore; Jessica Ezzell Hunter; Galen Joseph; Stephanie A Kraft; Jamilyn M Zepp; Sapna Syngal; Benjamin S Wilfond; Katrina A B Goddard
Journal:  JCO Precis Oncol       Date:  2021-11-03

5.  Risk-reducing surgery in unaffected individuals receiving cancer genetic testing in an integrated health care system.

Authors:  Sarah Knerr; Boya Guo; Kathleen F Mittendorf; Heather Spencer Feigelson; Marian J Gilmore; Gail P Jarvik; Tia L Kauffman; Erin Keast; Frances L Lynch; Kristin R Muessig; Sonia Okuyama; David L Veenstra; Jamilyn M Zepp; Katrina A B Goddard; Beth Devine
Journal:  Cancer       Date:  2022-06-09       Impact factor: 6.921

6.  Chemoprevention of endometrial cancer in Lynch syndrome: a step forward.

Authors:  Elena M Stoffel; Christine Walsh
Journal:  Cancer Prev Res (Phila)       Date:  2013-07-10

7.  Spectrum of mismatch repair gene mutations and clinical presentation of Hispanic individuals with Lynch syndrome.

Authors:  Annette Y Sunga; Charité Ricker; Carin R Espenschied; Danielle Castillo; Marilena Melas; Josef Herzog; Sarah Bannon; Marcia Cruz-Correa; Patrick Lynch; Ilana Solomon; Stephen B Gruber; Jeffrey N Weitzel
Journal:  Cancer Genet       Date:  2017-02-09

8.  Decisions about prophylactic gynecologic surgery: a qualitative study of the experience of female Lynch syndrome mutation carriers.

Authors:  Holly Etchegary; Elizabeth Dicks; Kathy Watkins; Sabrina Alani; Lesa Dawson
Journal:  Hered Cancer Clin Pract       Date:  2015-03-19       Impact factor: 2.857

9.  When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives.

Authors:  Scott D Grosse
Journal:  Healthcare (Basel)       Date:  2015-09-24

10.  Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk.

Authors:  Gregory E Idos; Allison W Kurian; Charité Ricker; Duveen Sturgeon; Julie O Culver; Kerry E Kingham; Rachel Koff; Nicolette M Chun; Courtney Rowe-Teeter; Alexandra P Lebensohn; Peter Levonian; Katrina Lowstuter; Katlyn Partynski; Christine Hong; Meredith A Mills; Iva Petrovchich; Cindy S Ma; Anne-Renee Hartman; Brian Allen; Richard J Wenstrup; Johnathan M Lancaster; Krystal Brown; John Kidd; Brent Evans; Bhramar Mukherjee; Kevin J McDonnell; Uri Ladabaum; James M Ford; Stephen B Gruber
Journal:  JCO Precis Oncol       Date:  2019-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.